MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Prostate Cancer Treatment and Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,880 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,880 works in the cohort · of 4,299,418page 36 of 78

Labels cover 13 of 3,880 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,880 of 3,880 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
18F-DCFPyL PET/CT in Oncocytoma
Jeremy Li, Richard Huan Xu, Chun K. Kim, François Bénard, Anil Kapoor, Glenn Bauman +1 more
2018· article· en· Clinical Nuclear Medicine· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone.
Kim N., Ulka N. Vaishampayan, Michael S. Gordon, David C. Smith, Erin Rudsinski, Angela De Haas-Amatsaleh +3 more
2017· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
Christopher J. Sweeney, Andrew Martin, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu +14 more
2019· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
venueno affno abstractunlabeled
10.1016/j.ymed.2014.08.035
2000· article· en· Time to knit· Medicine
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
6
citations
afffundunlabeled
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
Christos E. Kyriakopoulos, Gurkamal Chatta, Andrew Leonard Laccetti, Nicholas Iannotti, Alexandra Sokolova, Sebastién J. Hotte +10 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
venueno affno abstractunlabeled
10.1016/j.ymed.2015.06.114
2000· article· en· Time to knit· Medicine
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
6
citations
← previousnext →

How this was built: Screen · Findings · About